Year: 2012
Type: article
Abstract: and that dialing down CXCR4 signaling is an ideal therapeutic strategy.In the future, it may help accelerate preclinical development of drug candidates while continuing to reveal surprising new concepts about pathogenesis and the normal role of CXCR4 in hematopoiesis.Conflict-of-interest disclosure: The authors declare no competing financial interests.■
Source: Blood
Author: Kenneth Shain
Institution: Moffitt Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4245853668